Archaeosome Adjuvant Overcomes Tolerance to Tumor-Associated Melanoma Antigens Inducing Protective CD8+ T Cell Responses
2010

Archaeosome Adjuvant and Tumor Immunity

Sample size: 5 publication 10 minutes Evidence: moderate

Author Information

Author(s): Krishnan Lakshmi, Deschatelets Lise, Stark Felicity C., Gurnani Komal, Sprott G. Dennis

Primary Institution: National Research Council of Canada, Institute for Biological Sciences, Ottawa, ON, Canada

Hypothesis

Can archaeosome adjuvants overcome tolerance to tumor-associated melanoma antigens and induce protective CD8+ T cell responses?

Conclusion

Archaeosome adjuvants effectively induce strong CD8+ T cell responses and provide protection against melanoma.

Supporting Evidence

  • Vaccination with melanoma antigenic peptides delivered in archaeosomes resulted in strong CD8+ T cell responses.
  • Archaeosome formulations provided therapeutic protection against established tumors when combined with T-regulatory cell depletion.
  • Prime-boost vaccination with archaeosomes led to superior tumor protection compared to single-dose regimens.

Takeaway

Researchers found that a special type of vaccine called archaeosomes can help the body fight cancer by making immune cells called T cells work better.

Methodology

Mice were vaccinated with archaeosome formulations containing melanoma peptides and their immune responses were measured.

Potential Biases

Potential bias in the selection of animal models and the specific peptides used.

Limitations

The study's sample size was small, which may affect the generalizability of the results.

Participant Demographics

Inbred, 6–8-week-old female C57BL/6J mice.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1155/2010/578432

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication